Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Company Analysis

RXII Insider Trading

Phio Pharmaceuticals Corp. | Pharmaceutical Preparations

Comprehensive Trading Performance Summary

The investment history of corporate insiders at Phio Pharmaceuticals Corp. provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Pharmaceutical Preparations sector.

Transactions on Chart

Open Full Chart
Filing Date Trade Date Reporting Person Relationship Type Price Qty Total, $ Owned After Change, %
2013-08-20 16:50 2013-08-19 CAUWENBERGH GEERT Director, Officer - President & CEO BUY $3.72 320 $1,191 11,320 +2.9%
2013-08-06 18:25 2013-08-05 CAUWENBERGH GEERT Director, Officer - President & CEO BUY $4.02 1,000 $4,022 11,000 +10.0%
2013-08-05 23:43 2013-08-05 Bitterman Robert J Director BUY $4.08 1,000 $4,083 1,000 +100.0%
2013-07-31 23:15 2013-07-31 CAUWENBERGH GEERT Director, Officer - President & CEO BUY $4.02 167 $671 10,000 +1.7%
2013-07-31 18:35 2013-07-31 CAUWENBERGH GEERT Director, Officer - President & CEO BUY $4.10 500 $2,050 9,833 +5.4%
2013-07-30 17:01 2013-07-29 CAUWENBERGH GEERT Director, Officer - President & CEO BUY $4.54 500 $2,270 9,333 +5.7%
2013-07-29 20:34 2013-07-26 CAUWENBERGH GEERT Director, Officer - President & CEO BUY $4.87 500 $2,435 8,833 +6.0%
2013-05-03 01:57 2013-04-30 Galena Biopharma, Inc. 10% owner SELL $0.20 1,083,500 $211,716 32,393,095 -3.2%
2011-04-20 18:09 2011-04-20 Ahn Mark J Director, Officer - President and CEO BUY $0.95 10,000 $9,500 10,000 +100.0%
2010-12-31 00:29 2010-12-29 CYTRX CORP 10% owner SELL $2.20 2,593,881 $5,706,538 0 -100.0%
2010-12-24 00:34 2010-12-22 CYTRX CORP 10% owner SELL $2.65 500,000 $1,325,000 2,593,881 -16.2%
2010-07-22 01:56 2010-07-19 Varanasi Ramani Officer - VP Business Development SELL $2.05 5,000 $10,266 5,558 -47.4%
2010-07-12 22:23 2010-07-09 Beerman Noah D Director, Officer - CEO and President BUY $2.23 10,000 $22,292 15,407 +184.9%
2010-07-02 19:59 2010-06-30 CYTRX CORP 10% owner SELL $2.55 2,000,000 $5,100,000 3,093,881 -39.3%
2010-07-02 19:48 2010-03-26 CYTRX CORP 10% owner SELL $5.70 675,000 $3,847,500 5,093,881 -11.7%
2010-04-02 16:59 2010-03-31 Samarsky Dmitry Officer - VP, Technology Development SELL $4.65 4,081 $18,977 0 -100.0%
2010-03-31 00:46 2010-03-26 Hillsberg Sanford Director SELL $5.66 25,000 $141,500 6,000 -80.6%
2010-03-31 00:45 2010-03-26 GALLIKER STEPHEN S Director SELL $5.54 15,000 $83,100 10,000 -60.0%
2009-09-26 00:22 2009-09-23 CYTRX CORP 10% owner SELL $2.50 500,000 $1,250,000 5,768,881 -8.0%
2009-08-20 19:03 2009-08-19 KRIEGSMAN STEVEN A Director SELL $3.13 8,990 $28,157 0 -100.0%
2009-07-06 18:44 2009-07-01 KRIEGSMAN STEVEN A Director SELL $4.33 2,893 $12,516 8,988 -24.3%
2009-07-01 18:20 2009-06-29 KRIEGSMAN STEVEN A Director SELL $4.53 4,700 $21,274 11,881 -28.3%
2009-06-29 18:05 2009-06-25 KRIEGSMAN STEVEN A Director SELL $4.57 6,100 $27,876 16,581 -26.9%
2009-06-25 19:35 2009-06-23 KRIEGSMAN STEVEN A Director SELL $4.64 1,100 $5,109 22,681 -4.6%
2009-06-23 23:22 2009-06-19 KRIEGSMAN STEVEN A Director SELL $4.70 2,900 $13,638 23,781 -10.9%
2009-06-19 17:45 2009-06-17 KRIEGSMAN STEVEN A Director SELL $4.67 2,601 $12,157 26,681 -8.9%
2009-06-17 18:18 2009-06-15 KRIEGSMAN STEVEN A Director SELL $4.73 1,600 $7,572 29,282 -5.2%
2009-06-15 23:28 2009-06-11 KRIEGSMAN STEVEN A Director SELL $5.01 3,600 $18,053 30,882 -10.4%
2009-06-11 23:22 2009-06-09 KRIEGSMAN STEVEN A Director SELL $4.98 5,200 $25,884 34,482 -13.1%
2009-06-09 19:49 2009-06-05 KRIEGSMAN STEVEN A Director SELL $5.02 4,800 $24,079 39,682 -10.8%
2009-06-05 23:34 2009-06-03 KRIEGSMAN STEVEN A Director SELL $5.02 5,000 $25,118 44,482 -10.1%
2009-06-03 19:06 2009-06-01 KRIEGSMAN STEVEN A Director SELL $5.11 13,084 $66,868 49,482 -20.9%
2009-06-01 19:24 2009-05-28 KRIEGSMAN STEVEN A Director SELL $5.71 4,000 $22,847 62,566 -6.0%
2009-05-28 15:20 2009-05-26 KRIEGSMAN STEVEN A Director SELL $6.00 4,800 $28,803 66,566 -6.7%
2009-05-13 17:34 2009-05-11 KRIEGSMAN STEVEN A Director SELL $4.93 700 $3,450 71,366 -1.0%
2009-05-11 18:05 2009-05-07 KRIEGSMAN STEVEN A Director SELL $4.67 5,256 $24,528 72,066 -6.8%
2009-05-07 18:00 2009-05-05 KRIEGSMAN STEVEN A Director SELL $4.28 9,551 $40,909 77,322 -11.0%
2009-05-05 20:17 2009-05-01 KRIEGSMAN STEVEN A Director SELL $4.80 5,100 $24,457 86,873 -5.5%
2009-05-01 21:02 2009-04-29 KRIEGSMAN STEVEN A Director SELL $4.82 7,200 $34,686 91,973 -7.3%
2009-04-29 23:57 2009-04-27 KRIEGSMAN STEVEN A Director SELL $4.71 2,900 $13,659 99,173 -2.8%
2009-04-27 22:20 2009-04-23 KRIEGSMAN STEVEN A Director SELL $4.72 4,800 $22,652 102,073 -4.5%
2009-04-23 22:55 2009-04-21 KRIEGSMAN STEVEN A Director SELL $4.79 2,900 $13,886 106,873 -2.6%
2009-04-22 00:11 2009-04-17 KRIEGSMAN STEVEN A Director SELL $4.73 3,400 $16,098 109,773 -3.0%
2009-04-17 19:14 2009-04-15 KRIEGSMAN STEVEN A Director SELL $4.79 5,300 $25,411 113,173 -4.5%
2009-04-16 01:01 2009-04-13 KRIEGSMAN STEVEN A Director SELL $4.95 8,000 $39,587 118,473 -6.3%
2009-04-13 23:45 2009-04-09 KRIEGSMAN STEVEN A Director SELL $4.92 1,200 $5,898 126,473 -0.9%
2009-04-13 23:39 2009-04-08 KRIEGSMAN STEVEN A Director SELL $4.80 2,400 $11,519 127,673 -1.8%
2009-04-08 19:45 2009-04-06 KRIEGSMAN STEVEN A Director SELL $4.64 3,209 $14,903 130,073 -2.4%
2009-04-06 21:20 2009-04-02 KRIEGSMAN STEVEN A Director SELL $4.78 4,500 $21,490 133,282 -3.3%
2009-04-02 19:56 2009-03-31 KRIEGSMAN STEVEN A Director SELL $5.22 8,643 $45,132 137,782 -5.9%
SHOW ENTRIES

How to Interpret $RXII Trades

Not every insider transaction in Phio Pharmaceuticals Corp. is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $RXII shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.

Data Source & Accuracy for RXII

Insider activity data for Phio Pharmaceuticals Corp. is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $RXII, allowing you to follow the capital of those with the most intimate knowledge of the company.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.